Dennis Chen

Corporate Officer/Principal presso PROMIS NEUROSCIENCES, INC.

Health Technology

Profilo

Dennis Chen is currently the Head of Manufacturing at ProMIS Neurosciences, Inc. He previously worked as the Director of Process Development & Manufacturing at Geron Corp.
and as the Director of CMC Regulatory Affairs at Intarcia Therapeutics, Inc.

Posizioni attive di Dennis Chen

Società	Posizione	Inizio
PROMIS NEUROSCIENCES, INC.	Corporate Officer/Principal	-

Tutte le posizioni attive di Dennis Chen

Precedenti posizioni note di Dennis Chen

Società	Posizione	Fine
GERON CORPORATION	Corporate Officer/Principal	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Dennis Chen

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Dennis Chen

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
PROMIS NEUROSCIENCES, INC.	Health Technology
GERON CORPORATION	Health Technology

Aziende private	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology